Professor Alanne identified PIAS3 as a potential biomarker for Gleason score 4 + 3 = 7 for prostate cancer and UBE2V2 as a potential biomarker for Gleason score 6, while Professor ElKarami created a model for predicting upgrading on magnetic resonance imaging targeted biopsy by machine learning (22, 23). Here, PIAS3 is linked to prostate carcinoma.